Mer­ck clinch­es pri­or­i­ty re­view for pneu­mo­coc­cal vac­cine, rais­ing stakes for Pfiz­er

The FDA on Tues­day grant­ed Mer­ck pri­or­i­ty re­view for its in­ves­ti­ga­tion­al pneu­mo­coc­cal vac­cine, mak­ing strides ahead of Pfiz­er in the com­pa­nies’ years­long con­test atop the mar­ket for the vac­cines.

The pri­or­i­ty re­view was award­ed for Mer­ck’s V116, a 21-va­lent vac­cine to pre­vent pneu­mo­coc­cal dis­ease and pneu­mo­coc­cal pneu­mo­nia in adults. The FDA is plan­ning to make a de­ci­sion on ap­proval by June 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER